Author response for "Efficacy and safety of polyethylene glycol loxenatide ( PEX168 ) monotherapy in type 2 diabetes patients: a multicenter, randomized, double‐blind, placebo‐controlled, phase 3a clinical trial"
Keyword(s):
2020 ◽
Keyword(s):
2020 ◽
Keyword(s):
2020 ◽
Keyword(s):
2020 ◽
Keyword(s):
2020 ◽
Keyword(s):
2020 ◽
Keyword(s):
2020 ◽
Keyword(s):
2020 ◽
Keyword(s):
2020 ◽
Keyword(s):
2020 ◽
Keyword(s):